PureTech Health plc (LON: PRTC)

London flag London · Delayed Price · Currency is GBP · Price in GBX
171.20
+9.20 (5.68%)
Nov 22, 2024, 4:35 PM BST
3.88%
Market Cap 409.89M
Revenue (ttm) 370.31K
Net Income (ttm) -65.25M
Shares Out 239.42M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 519,048
Open 160.00
Previous Close 162.00
Day's Range 160.00 - 171.20
52-Week Range 138.75 - 238.50
Beta 1.02
Analysts n/a
Price Target n/a
Earnings Date Nov 28, 2024

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 90
Stock Exchange London Stock Exchange
Ticker Symbol PRTC
Full Company Profile

Financial Performance

In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.

Financial numbers in USD Financial Statements

News

CITIGROUP INC Acquires New Stake in PureTech Health PLC

CITIGROUP INC Acquires New Stake in PureTech Health PLC

9 days ago - GuruFocus

PureTech to Present at CHEST 2024 Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech to Present at CHEST 2024 Annual Meeting.

7 weeks ago - Business Wire

PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript

PureTech Health plc (NASDAQ:NASDAQ:PRTC) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ETCompany ParticipantsAllison Mead Talbot - Head of...

3 months ago - Seeking Alpha

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.

3 months ago - Business Wire

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

3 months ago - Business Wire

PureTech Health: Results of the Tender Offer

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.

5 months ago - Business Wire

PureTech Announces Change of Board Role

BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.

5 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team.

5 months ago - Business Wire

PureTech Health: Results of Annual General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of AGM.

5 months ago - Business Wire

PureTech Health: Result of General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Result of General Meeting.

6 months ago - Business Wire

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.

6 months ago - Business Wire

PureTech to Present at the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.

6 months ago - Business Wire

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.

6 months ago - Business Wire

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

BOSTON--(BUSINESS WIRE)--PureTech Health: Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share.

6 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting.

7 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments.

7 months ago - Business Wire

PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript

PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head, Communications Bharatt Chowrira - Chief Executive Officer...

7 months ago - Seeking Alpha

PureTech Announces Annual Results for Year Ended December 31, 2023

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2023.

7 months ago - Business Wire

PureTech Health: Notice of Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.

7 months ago - Business Wire

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

BOSTON--(BUSINESS WIRE)--PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis.

7 months ago - Business Wire

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers.

8 months ago - Business Wire

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

BOSTON--(BUSINESS WIRE)--PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions.

8 months ago - Business Wire

PureTech Health: Repeat What Works

PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's le...

8 months ago - Seeking Alpha

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded...

8 months ago - Business Wire

PureTech to Present at Two Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastat...

9 months ago - Business Wire